Immunoglobulin Replacement Therapy Not Associated With Reduced Risk of Infection-Related Hospitalizations Among Patients with CLL
Patients with chronic lymphocytic leukemia (CLL) can experience infections as a result of immune suppression and dysregulation of the immune system from treatments and the disease ...
Individualized Therapy Associated With Greater Rates of Undetectable MRD, Extended PFS in CLL
According to a study published in the New England Journal of Medicine, measurable residual disease (MRD)-guided therapy with the BTK inhibitor ibrutinib plus venetoclax in patients ...
Patients With CMML Show Durable Response to Lenzilumab, Azacitidine Combo
Multiple subgroups of patients with high-risk chronic myelomonocytic leukemia (CMML) showed durable responses to the combination of lenzilumab plus azacitidine ...
Results Detail Comparison of Patients With R/R CLL/SLL in Liso-Cel TRANSCEND CLL 004 Trial With Real-World SOC Cohort
The U.S. Food and Drug Administration approved lisocabtagene maraleucel (liso-cel) on March 15, 2025, for patients with relapsed or refractory chronic lymphocytic leukemia ...
Patients With R/R CLL/SLL Achieve Tumor Response With DZD8586
Patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R/R CLL/SLL) need therapies beyond covalent and non-covalent BTK inhibitors ...
Five-Year Results of SEQUOIA Trial Show Maintenance of Benefit for Patients With Del(17p) Treatment-Naïve CLL Treated With Zanubrutinib
The initial results from the SEQUOIA study showed that patients with treatment-naïve chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without ...
Zanubrutinib Plus Venetoclax Shows Efficacy in Treatment-Naïve CLL/SLL
The combination of the BTK inhibitor zanubrutinib and the BCL2 inhibitor venetoclax for treatment-naïve chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma ...
MRD-Guided Treatment Approach Leads to Deep Remissions in CLL
Measurable residual disease (MRD)-guided time-limited treatment showed deep remission in previously treated patients with chronic lymphocytic leukemia (CLL) ...
Fixed-Duration Acalabrutinib Combinations Effective for Untreated CLL
The interim analysis of data from the AMPLIFY clinical trial indicates that for fit patients with previously untreated chronic lymphocytic leukemia (CLL) ...
Bispecific Antibody Elicits High Responses Among Patients With Heavily Pretreated CLL
Patients with heavily pretreated, relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) treated with epcoritamab, a bispecific antibody, had a high overall response rate ...
